Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae-Reference-Cited by-同舟云学术

Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pacios Olga¹^ORCID,Fernández-García Laura¹^ORCID,Bleriot Ines¹^ORCID,Blasco Lucía¹^ORCID,González-Bardanca Mónica¹,López María¹²,Fernández-Cuenca Felipe³²,Oteo Jesús⁴²^ORCID,Pascual Álvaro³²,Martínez-Martínez Luis⁵²,Domingo-Calap Pilar⁶^ORCID,Bou Germán¹²,Tomás María¹²^ORCID

Affiliation:

1. Microbiology Department, Research Institute Biomedical A Coruña (INIBIC), Hospital A Coruña (CHUAC), University of A Coruña (UDC), A Coruña, Spain

2. Spanish Network for Research in Infectious Diseases (REIPI), Seville, Spain

3. UGC Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Seville, Spain

4. National Centre for Microbiology, Spanish Network for Research in Infectious Diseases, Institute of Health Carlos III, Madrid, Spain

5. UGC Microbiología, Hospital Reina Sofía, Departamento de Microbiología, Universidad de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain

6. Institute for Integrative Systems Biology (I2SysBio), Universitat de València-CSIC, Valencia, Spain

Abstract

Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13.

Funder

MEC | Instituto de Salud Carlos III

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00900-21

Reference60 articles.

1. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance

2. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance

Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice